Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Featured News

    PTx Acquires Potential Radiation Sickness Therapeutic from Sanofi

    By Global Biodefense StaffFebruary 27, 2018
    Biodefense Industry News
    Share
    Facebook LinkedIn Reddit Email

    Boston-based cancer company Partner Therapeutics, Inc. (PTx) has acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.

    Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body’s immune response to fight infections. Leukine is used to treat or prevent severe and life-threatening infections and is the only immune modulator approved by the FDA for the treatment of acute myelogenous leukemia (AML) in older patients and for use in both allogeneic and autologous bone marrow transplantation.

    PTx will support the development of Leukine for new indications, including for the treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (H-ARS). Data presented at the 2016 annual meeting of the American Society of Hematology, demonstrated Leukine’s ability to increase survival in non-human primates exposed to myelosuppressive doses of radiation without supportive whole blood transfusions or individualized antibiotics. A supplemental biologics licensing application (sBLA) was filed in September of 2017 with the FDA requesting approval of Leukine for the treatment of H-ARS. In December, the application was granted Priority Review with a PDUFA date of March 29, 2018.

    Leukine is also in development for its potential to improve survival and reduce adverse events in combination with leading immuno-oncology therapies.

    “The acquisition of Leukine provides us with an established commercial business, a product that has demonstrated a clear and substantial impact on outcomes, and a program with the potential to become a core component of immuno-oncology, the treatment of acute radiation syndrome and the treatment of infections,” said Robert Mulroy, CEO of PTx.

    PTx plans to provide commercial and medical support of Leukine in the United States and explore commercialization opportunities outside the U.S.

    Source: Partner Therapeutics, edited for context and format by Global Biodefense.

    Radiation
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleZMapp Ebola Treatment to be Tested at Texas Biomed
    Next Article MIT, USAMRIID Develop Algorithm for Early Warning of Exposure to Pathogens

    Related Stories

    Impact of COVID-19 Pandemic on Emergency Department Use in British Columbia

    September 5, 2023

    Distrust Undermined the U.S. Pandemic Response and Continues to Erode Healthcare

    August 29, 2023

    Applying Lessons Learned from COVID-19 Research and Development to Future Epidemics

    August 27, 2023

    Imunon Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus

    August 24, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    Oct 17
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Dispensing and Administration of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.